Hyperfine (HYPR) Competitors

$1.50 +0.02 (+1.35%)

Closing price 04:00 PM Eastern

Extended Trading

$1.47 -0.03 (-1.80%)

As of 08:00 PM Eastern

HYPR vs. BWAY, AVR, CBLL, SIBN, and NPCE

Should you buy Hyperfine stock or one of its competitors? MarketBeat compares Hyperfine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hyperfine include Brainsway (BWAY), Anteris Technologies Global (AVR), CeriBell (CBLL), SiBone (SIBN), and NeuroPace (NPCE). These companies are all part of the "medical equipment" industry.

How does Hyperfine compare to Brainsway?

Brainsway (NASDAQ:BWAY) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Brainsway has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.22M	11.56	$7.57M	$0.35	43.09
Hyperfine	$11.40M	12.89	-$35.57M	-$0.41	N/A

Brainsway presently has a consensus price target of $15.00, indicating a potential downside of 0.53%. Hyperfine has a consensus price target of $1.78, indicating a potential upside of 18.89%. Given Hyperfine's higher probable upside, analysts plainly believe Hyperfine is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Brainsway has a net margin of 15.68% compared to Hyperfine's net margin of -226.88%. Brainsway's return on equity of 12.28% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.68%	12.28%	7.75%
Hyperfine	-226.88%	-98.83%	-67.09%

Brainsway has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Hyperfine has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market.

30.1% of Brainsway shares are owned by institutional investors. Comparatively, 15.0% of Hyperfine shares are owned by institutional investors. 19.0% of Brainsway shares are owned by company insiders. Comparatively, 26.3% of Hyperfine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Hyperfine had 1 more articles in the media than Brainsway. MarketBeat recorded 3 mentions for Hyperfine and 2 mentions for Brainsway. Brainsway's average media sentiment score of 0.24 beat Hyperfine's score of 0.00 indicating that Brainsway is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainsway	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hyperfine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Brainsway beats Hyperfine on 10 of the 15 factors compared between the two stocks.

How does Hyperfine compare to Anteris Technologies Global?

Anteris Technologies Global (NASDAQ:AVR) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Anteris Technologies Global currently has a consensus price target of $16.00, indicating a potential upside of 77.78%. Hyperfine has a consensus price target of $1.78, indicating a potential upside of 18.89%. Given Anteris Technologies Global's stronger consensus rating and higher possible upside, research analysts clearly believe Anteris Technologies Global is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Hyperfine has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$1.91M	458.67	-$94.14M	-$2.23	N/A
Hyperfine	$11.40M	12.89	-$35.57M	-$0.41	N/A

15.0% of Hyperfine shares are owned by institutional investors. 4.5% of Anteris Technologies Global shares are owned by insiders. Comparatively, 26.3% of Hyperfine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Hyperfine has a net margin of -226.88% compared to Anteris Technologies Global's net margin of -5,148.78%. Hyperfine's return on equity of -98.83% beat Anteris Technologies Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	-5,148.78%	-124.76%	-101.21%
Hyperfine	-226.88%	-98.83%	-67.09%

Anteris Technologies Global has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, Hyperfine has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

In the previous week, Hyperfine had 1 more articles in the media than Anteris Technologies Global. MarketBeat recorded 3 mentions for Hyperfine and 2 mentions for Anteris Technologies Global. Hyperfine's average media sentiment score of 0.00 beat Anteris Technologies Global's score of -0.08 indicating that Hyperfine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anteris Technologies Global	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hyperfine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Hyperfine beats Anteris Technologies Global on 12 of the 16 factors compared between the two stocks.

How does Hyperfine compare to CeriBell?

CeriBell (NASDAQ:CBLL) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Hyperfine has lower revenue, but higher earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	7.98	-$53.41M	-$1.63	N/A
Hyperfine	$11.40M	12.89	-$35.57M	-$0.41	N/A

CeriBell has a net margin of -63.51% compared to Hyperfine's net margin of -226.88%. CeriBell's return on equity of -38.19% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Hyperfine	-226.88%	-98.83%	-67.09%

CeriBell presently has a consensus target price of $22.20, indicating a potential upside of 18.46%. Hyperfine has a consensus target price of $1.78, indicating a potential upside of 18.89%. Given Hyperfine's higher probable upside, analysts plainly believe Hyperfine is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

15.0% of Hyperfine shares are owned by institutional investors. 20.1% of CeriBell shares are owned by company insiders. Comparatively, 26.3% of Hyperfine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, CeriBell had 2 more articles in the media than Hyperfine. MarketBeat recorded 5 mentions for CeriBell and 3 mentions for Hyperfine. CeriBell's average media sentiment score of 0.57 beat Hyperfine's score of 0.00 indicating that CeriBell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperfine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CeriBell has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, Hyperfine has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

Summary

CeriBell beats Hyperfine on 9 of the 17 factors compared between the two stocks.

How does Hyperfine compare to SiBone?

Hyperfine (NASDAQ:HYPR) and SiBone (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Hyperfine has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, SiBone has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

SiBone has higher revenue and earnings than Hyperfine. SiBone is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	12.89	-$35.57M	-$0.41	N/A
SiBone	$200.93M	3.27	-$18.90M	-$0.39	N/A

Hyperfine presently has a consensus price target of $1.78, indicating a potential upside of 18.89%. SiBone has a consensus price target of $23.00, indicating a potential upside of 55.30%. Given SiBone's stronger consensus rating and higher probable upside, analysts clearly believe SiBone is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

SiBone has a net margin of -8.10% compared to Hyperfine's net margin of -226.88%. SiBone's return on equity of -9.56% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
SiBone	-8.10%	-9.56%	-7.06%

In the previous week, SiBone had 1 more articles in the media than Hyperfine. MarketBeat recorded 4 mentions for SiBone and 3 mentions for Hyperfine. SiBone's average media sentiment score of 0.11 beat Hyperfine's score of 0.00 indicating that SiBone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 26.3% of Hyperfine shares are held by company insiders. Comparatively, 4.0% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

SiBone beats Hyperfine on 12 of the 16 factors compared between the two stocks.

How does Hyperfine compare to NeuroPace?

Hyperfine (NASDAQ:HYPR) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Hyperfine has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, NeuroPace has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

NeuroPace has higher revenue and earnings than Hyperfine. NeuroPace is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	12.89	-$35.57M	-$0.41	N/A
NeuroPace	$99.99M	5.55	-$21.47M	-$0.65	N/A

NeuroPace has a net margin of -21.67% compared to Hyperfine's net margin of -226.88%. Hyperfine's return on equity of -98.83% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
NeuroPace	-21.67%	-108.20%	-18.50%

In the previous week, NeuroPace had 10 more articles in the media than Hyperfine. MarketBeat recorded 13 mentions for NeuroPace and 3 mentions for Hyperfine. NeuroPace's average media sentiment score of 0.67 beat Hyperfine's score of 0.00 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroPace	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 26.3% of Hyperfine shares are held by company insiders. Comparatively, 20.5% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Hyperfine presently has a consensus price target of $1.78, indicating a potential upside of 18.89%. NeuroPace has a consensus price target of $18.83, indicating a potential upside of 15.68%. Given Hyperfine's higher probable upside, research analysts clearly believe Hyperfine is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

NeuroPace beats Hyperfine on 11 of the 17 factors compared between the two stocks.

Get Hyperfine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYPR vs. The Competition

Export

Metric	Hyperfine	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$144.98M	$7.15B	$6.34B	$12.29B
Dividend Yield	N/A	1.67%	2.79%	5.33%
P/E Ratio	-3.66	50.13	21.09	25.40
Price / Sales	12.89	72.25	528.21	79.15
Price / Cash	N/A	25.00	44.13	56.13
Price / Book	4.29	6.51	9.99	7.01
Net Income	-$35.57M	$158.81M	$3.55B	$335.05M
7 Day Performance	-6.25%	2.22%	0.42%	-0.29%
1 Month Performance	17.19%	-0.75%	-0.05%	1.15%
1 Year Performance	154.24%	2.02%	35.06%	34.79%

Hyperfine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYPR Hyperfine	2.879 of 5 stars	$1.50 +1.4%	$1.78 +18.9%	+137.8%	$144.98M	$11.40M	N/A	190
BWAY Brainsway	2.4701 of 5 stars	$16.74 +0.1%	$15.00 -10.4%	+185.9%	$670.27M	$52.22M	66.96	120
AVR Anteris Technologies Global	2.8899 of 5 stars	$6.70 +2.9%	$15.33 +128.9%	+125.7%	$651.44M	$1.91M	N/A	138
CBLL CeriBell	2.3031 of 5 stars	$16.75 -16.5%	$22.20 +32.5%	-0.4%	$634.32M	$89.06M	N/A	N/A	High Trading Volume
SIBN SiBone	2.6116 of 5 stars	$13.90 +19.7%	$23.00 +65.5%	-24.8%	$614.94M	$200.93M	N/A	350	Insider Trade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYPR) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hyperfine (HYPR) Competitors